The Effectiveness of Cinacalcet as an Adjunctive Therapy for Hereditary 1,25 Dihydroxyvitamin D3-Resistant Rickets

Basit Öğe Kaydı
dc.authoridAkinci, Aysehan/0000-0001-7267-9444
dc.authoridDundar, Ismail/0000-0003-1468-6405
dc.authoridDundar, Ismail/0000-0003-1468-6405
dc.authorwosidAkinci, Aysehan/AAC-6847-2021
dc.authorwosidDundar, Ismail/ABG-2027-2021
dc.authorwosidDundar, Ismail/AAA-2528-2021
dc.contributor.authorAkinci, Aysehan
dc.contributor.authorDundar, Ismail
dc.contributor.authorKivilcim, Meltem
dc.date.accessioned2024-08-04T20:43:11Z
dc.date.available2024-08-04T20:43:11Z
dc.date.issued2017
dc.departmentİnönü Üniversitesien_US
dc.description.abstractHigh doses of oral calcium or long-term calcium infusions are recommended to correct the hypocalcemia and secondary hyperparathyroidism in patients with hereditary 1,25 dihydroxyvitamin D-3-resistant rickets (HVDRR). Preliminary studies revealed that calcimimetics may be a safe and effective therapeutic choice in children with secondary hyperparathyroidism. Our aim was to observe the efficacy of cinacalcet in the normalization of secondary hyperparathyroidism and hypophosphatemia in two siblings aged 2.5 years and 6 months with HVDRR who did not respond to traditional treatment regimes. Both patients were admitted to the hospital with severe hypocalcemia. They were treated with high doses of calcitriol and calcium infusions intravenously. Secondary hyperparathyroidism was normalized temporarily, but did not improve completely. Cinacalcet (0.25 mg/kg) once a day along with the high doses of oral calcium and calcitriol was added to the treatment schedule. After 3 months, biochemical and radiologic findings reverted to normal. Our findings indicate that cinacalcet is effective in normalizing the hyperparathyroidism and hypophosphatemia in these cases and in improving the bone pathology.en_US
dc.identifier.doi10.4274/jcrpe.3486
dc.identifier.endpage178en_US
dc.identifier.issn1308-5727
dc.identifier.issn1308-5735
dc.identifier.issue2en_US
dc.identifier.pmid27796266en_US
dc.identifier.scopus2-s2.0-85020182520en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage172en_US
dc.identifier.urihttps://doi.org/10.4274/jcrpe.3486
dc.identifier.urihttps://hdl.handle.net/11616/97841
dc.identifier.volume9en_US
dc.identifier.wosWOS:000406446700014en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofJournal of Clinical Research in Pediatric Endocrinologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCinacalceten_US
dc.subjecthereditary vitamin D-resistant ricketsen_US
dc.subjectsecondary hyperparathyroidismen_US
dc.titleThe Effectiveness of Cinacalcet as an Adjunctive Therapy for Hereditary 1,25 Dihydroxyvitamin D3-Resistant Ricketsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu